Medimmune

(Image: Getty/Bong Hyunjung)

MedImmune will cease to exist after 30 years

By Ben Hargreaves

In full-year financials, AstraZeneca announced that its R&D arm, MedImmune, will be absorbed into the overall company as it restructures its R&D units into specific therapy areas.

FluMist finally on track

FluMist finally on track

By Anna Lewcock

Manufacturing problems hindering production of MedImmune's
intranasal flu vaccine FluMist have finally been resolved at the
company's Liverpool, UK facility, with doses on track to be
available for this year's flu season.

MedImmune 'for sale'

MedImmune 'for sale'

By Emilie Reymond

Biotech company MedImmune has finally given in to recent pressure
from its shareholders and announced yesterday it is putting itself
up for sale.